Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services

The National Cancer Institute awarded a Master IDIQ to provide field preparation, biospecimen collection, and clinical support for the Division of Cancer Epidemiology and Genetics' domestic and international epidemiology and genetic research programs on July 1, 2022, with a shared ceiling of $320 million and ordering authority extending through June 30, 2027.

Eight task orders totaling $107.5 million in combined potential value have been issued to date, with $26.7 million obligated (25% of combined potential). The vehicle shows moderate ordering momentum, with five orders awarded in 2023 and three in 2024; the most recent order was placed on July 1, 2024, indicating continued active utilization. Ordering authority remains in effect for approximately eleven months.

Work spans multiple DCEG branches and laboratories, including the Metabolic Epidemiology Branch, Infections and Immunoepidemiology Branch, Integrative Tumor Epidemiology Branch, Clinical Genetics Branch, and Occupational and Environmental Epidemiology Branch, supporting large-scale retrospective and cohort studies, case-control studies, family studies, and randomized clinical trials across domestic and international sites. All task orders are cost-plus-fixed-fee arrangements with no set-aside designations.

Competition is highly concentrated: Westat, Inc. holds six of eight orders and $97.2 million of the $107.5 million combined potential value (90.4% of total), with American Type Culture Collection and Social & Scientific Systems, Inc. each holding one order. All customer activity flows through the National Cancer Institute. Individual task-order ceilings range from $3.4 million to $32.5 million, with durations extending from approximately two to eight years. The largest recent order (issued March 1, 2024 to Westat) carries a $32.5 million ceiling supporting the Infections and Immunoepidemiology and Integrative Tumor Epidemiology Branches through September 2031. Recent completions include the HPV-PAVE project, which closed on June 14, 2025 at its full $3.4 million ceiling.

Support field preparation, biospecimen collection, and clinical activities in support of, but not limited to, the ongoing epidemiology and genetic research programs, conducted in the Branches and Laboratories in DCEG which include large scale domestic and international studies with diverse study designs in epidemiology and genetics research including retrospective and cohort studies, case-control studies, family studies, and randomized clinical trials. These studies span several geographic areas (potentially in any continent), are of varying size and complexity, and include dense, high-dimensional data on exposures, endpoints, clinical information, and biomarkers from molecular technologies.